•
Jun 30, 2021
Nuvation Bio Q2 2021 Earnings Report
Nuvation Bio reported financial results for the second quarter ended June 30, 2021, and provided a business update.
Key Takeaways
Nuvation Bio reported a net loss of $19.3 million, or $(0.09) per share, and had cash, cash equivalents and marketable securities of $806.6 million as of June 30, 2021. They are advancing their supply chain and continuing to enroll patients in their Phase 1/2 study of NUV-422.
Ongoing enrollment in Phase 1/2 study of NUV-422 for the treatment of adult patients with malignant gliomas.
Protocol amendment submitted to expand into additional cancers.
Appointment of David C. Hanley, Ph.D., as Chief Technical Operations Officer.
Cash, cash equivalents and marketable securities of $806.6 million as of June 30, 2021.